Remynd announces a €3.5 million strategic investment from the Alzheimer's Drug Discovery Foundation (ADDF) in the clinical development of REM392, our lead candidate for the treatment of mild-to-moderate Alzheimer's disease. The investment will support a Phase 1b study in patients, expected to start in early 2027. The announcement comes on World Alzheimer’s Day, a day of international awareness for the millions of people affected by this disease and the urgent need for better treatments.

With deep sadness, we share that Johan Cardoen, Chairman of remynd’s Board and a cornerstone of the Belgian biotech community, has passed away.

Last year, we shared Phase 2a results from our Alzheimer’s program at CTAD in Madrid. With the full paper now published, we unpack what we tested, what we learned, and how it helps advance our search for better treatments.

Following the announcement of the first-in-human trial of our second-generation Alzheimer’s compound, the progress and potential of this investigational therapy were featured on VRT NWS and in De Ochtend on Radio 1 today.

We were pleased to welcome Federal Minister Jan Jambon this week for a visit at our facilities in Leuven, where he was introduced to our ongoing work in Alzheimer research and drug development.

Our ongoing Phase I study is progressing as planned, with the first results expected in early July.

AI-powered digital twins help interpret early signals in a small Phase 2a study of a novel therapy for Alzheimer’s disease

Leuven biotech player remynd announces its strategic transition into an organization purely focused on drug development

Results were presented this week at the 17th annual Clinical Trials in Alzheimer’s Disease (CTAD) conference in Madrid

remynd announces appointment of Floor Stam as CEO and Johan Cardoen as Chairman

We published a new study in Science revealing a promising strategy to combat Alzheimer’s disease.